Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 27CNS 3Endocrine 2Tumor-Agnostic 1Gynecologic 1Breast 1

Conditions

von Hippel-Lindau Disease 2Pheochromocytoma 2Paraganglioma 2Carcinoma, Renal Cell 2Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Kidney Neoplasms 1Hemangioblastoma 1Glioblastoma 1Adenoma, Islet Cell 1

Interventions

Temozolomide 623Radiotherapy 411Bevacizumab 257Magnetic Resonance Spectroscopy 227Cyclophosphamide 179Radiosurgery 163Carboplatin 160Etoposide 132Radiation 129Vincristine 115Irinotecan 115Cisplatin 103Filgrastim 100Specimen Handling 90Nivolumab 88pembrolizumab 84Surgical Procedures, Operative 83Lomustine 82Topotecan 73Doxorubicin 61Melphalan 59Carmustine 57Radiotherapy, Intensity-Modulated 56sargramostim 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 51Chemotherapy, Adjuvant 51Blood Specimen Collection 51Erlotinib Hydrochloride 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
belzutifan × CNS × Clear all
NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07167329 2025-09-11

BELIEVE-VHL

AC Camargo Cancer Center

Phase 2 Recruiting
100 enrolled
CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT02974738 2025-07-10

MK-6482-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting
120 enrolled
CNSGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡